Skip to main content
SpringerLink
Log in

Possible additional therapeutic uses of aromatase inhibitors

  • Chapter
Aromatase Inhibitors

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 402 Accesses

Abstract

Several excellent chapters in this book describe the clinical utility of aromatase inhibitors in the treatment of breast cancer. It is true to say that use of third-generation aromatase inhibitors has had a major therapeutic impact: emerging clinical evidence for some of them shows that they can achieve superior efficacy to tamoxifen, the gold standard of endocrine care for more than two decades.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmac Therap 25: 127–205

    Article  CAS  Google Scholar 

  2. Bowman A, Gabra H, Langdon SP, Lessells A et al. (2002) CA125 response is associated with oestrogen receptor expression in a Phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8: 2233–2239

    PubMed  CAS  Google Scholar 

  3. Papadimitriou CA, Markaki S, Siapkarasw J, Vlachos G et al. (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Oncology 66: 112–117

    Article  PubMed  CAS  Google Scholar 

  4. Krasner CN, Debernado RL, Findley M, Penson R et al. (2005) Phase II trial of ansastrazole in Combination with Gefitinib in Women with Asymtomatic Mullerian Cancer. Proc Am Soc Clin Oncol Abstract 5063

    Google Scholar 

  5. Sasano H, Sata S, Ito K, Yajima A et al. (1999) Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer 6: 197–204

    Article  PubMed  CAS  Google Scholar 

  6. Morsi H, Leers M, Nap M, Bjorklund V et al. (2000) Apoptosis and anti-apoptosis in oestrogenreceptor negative endometrial cancer cells in response to anastrozole, 4-hydroxytamoxifen and medroxyprogesterone acetate. Eur J Cancer 36(Suppl 4): 112–113

    Article  PubMed  Google Scholar 

  7. Rose PG, Brunetto VL, Vanle L, Bell J et al. (2000) A phase II trial of anastrozole in advanced recurrent or persistent edometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 78: 212–216

    Article  PubMed  CAS  Google Scholar 

  8. Berstein L, Maximov S, Gersgfeld E, Meshkova I et al. (2002) Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. Eur J Obstet Gynecol Reprod Biol 105: 161–165

    PubMed  CAS  Google Scholar 

  9. Ma BBY, Oza A, Eisenhauser E, Stanimir G et al. (2004) The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers — a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14: 650–658

    Article  PubMed  CAS  Google Scholar 

  10. Reich O, Regauger S, Urdl W, Lahousen M et al. (2000) Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 82: 1030–1034

    Article  PubMed  CAS  Google Scholar 

  11. Reich O, Regauer S (2004) Aromatase expression in low-grade endometrial stromal sarcomas. A immunohistochemical study. Mod Pathol 17: 104–108

    Article  PubMed  Google Scholar 

  12. Maluf FC, Sabbatini MD, Schwartz L, Xia J et al. (2001) Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 82: 384–388

    Article  PubMed  CAS  Google Scholar 

  13. Leunen M, Breugelmans M, De Sutter PH, Bourgain C et al. (2004) Low grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole: case report. Gynecol Oncol 95: 769–771

    Article  PubMed  CAS  Google Scholar 

  14. Spano JP, Soria JC, Kambouchner M, Piperno-Neuman et al. (2003) Long term survival of patients given hormonal therapy for endometrial stromal sarcoma. Med Oncol 94: 87–94

    Article  Google Scholar 

  15. Reich O, Regauer S (2005) Hormonal treatment with aromatase inhibitors for patients with endometrial sarcoma. Gynecol Oncol 98: 173–174

    Article  PubMed  CAS  Google Scholar 

  16. Santen RJ, Petroni GR, Fisch MJ, Myers CE et al. (2001) Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 92: 2095–2101

    Article  PubMed  CAS  Google Scholar 

  17. Smith MR, Kaufman D, George D, Oh WK et al. (2002) Selective aromatase inhibition for patients with androgen-independent prostate carcinoma: a Phase II study of letrozole. Cancer 95: 1864–1868

    Article  PubMed  CAS  Google Scholar 

  18. Bonomo M, Mingrone W, Brauchli P, Hering F et al. (2003) Exemestane seems to stimulate growth in men with prostate carcinoma. Eur J Cancer 39: 2111–2112

    Article  PubMed  Google Scholar 

  19. Grosh WW, Mueller S, Alexander BF, Caldwell SH et al. (1999) Anastrozole (A) treatment of patients (pts) with advanced unresectable hepatocellular carcinoma (HCC). Proc ASCO 18: 286a Abstract 1096

    Google Scholar 

  20. Mitwally MFM, Casper RF (2000) The aromatase inhibitor, Letrozole: a promising alternative for clomiphene citrate for induction of ovulation. Fertil Steril 74: S35–S37

    Article  Google Scholar 

  21. Mitwally MFM, Casper RF (2001) Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75: 305–309

    Article  PubMed  CAS  Google Scholar 

  22. Al-Omari WR, Sulaiman WR, Al-Hadithi N (2003) Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Gynecol Obstet 85: 289–291

    Article  CAS  Google Scholar 

  23. Park WI, Shin SY, Yang JS, Lee JY (2004) Clinical outcomes of ovulation induction with aromatase inhibitor: Prospective randomised comparison with clomiphene citrate. J Obstet Gynaecol Res 30: 262 Abstract 8–19

    Google Scholar 

  24. Elnashar AM (2002) Current uses of aromatase inhibitors in gynecology. Middle East Fertil Soc J 7: 173–179

    Google Scholar 

  25. Fisher SA, Reid MD, Van Vugt DA, Casper RF (2002) A randomised double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal woman. Fertil Steril 78: 280–285

    Article  PubMed  Google Scholar 

  26. Sammour A, Biljan MM, Tan SL, Tulandi T (2001) Prospective randomised trial comparing the effects of letrozole and clomiphene citrate on follicular development, endometrial thickness and pregnancy rate in patients undergoing superovulation prior to intrauterine insemination. Fertil Steril 76: S110–S112

    Article  Google Scholar 

  27. Mousavi-Fatemi H, Kolibiankis E, Tournaye H, Camus M et al. (2003) Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Bio Med Online 7: 543–546

    Article  Google Scholar 

  28. El Helw B, El Sadek M, Matar H, Fouad S et al. (2002) Single dose Letrozole versus CC for superovulation prior to intrauterine insemination: a prospective randomised study. Hum Reprod 17: Abstract 73

    Google Scholar 

  29. Mitwally MFM, Casper RF (2002) Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 77: 776–780

    Article  PubMed  Google Scholar 

  30. Mitwally MFM, Casper RF (2003) Aromatase inhibition reduced gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 18: 1588–1597

    Article  PubMed  CAS  Google Scholar 

  31. Mitwally MFM, Casper RF (2004) Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynaecol Invest 11: 406–415

    Article  CAS  Google Scholar 

  32. Tsirigotis M, Prapas G, Pistofidis G, Tika M et al. (2002) Experience with the use of letrozole in patients with a history of poor ovarian response in previous assisted reproductive cycles. Hum Reprod 17: Abstract 34

    Google Scholar 

  33. Healey S, Lin Tan S, Tulandi T, Biljan MM (2003) Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertil Steril 80: 1325–1329

    Article  PubMed  Google Scholar 

  34. Casper RF (2003) Letrozole: ovulation or superovulation? Fertil Steril 80: 1335–1337

    Article  PubMed  Google Scholar 

  35. Noble LS, Simpson ER, Johns A, Bulun SE (1996) Aromatase expression in endometriosis. J Clin Endocr Metab 81: 174–179

    Article  PubMed  CAS  Google Scholar 

  36. Kitawaki J, Noguchi T, Amatsu T, Maeda K et al. (1997) Expression of aromatse cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but in normal endometrium. Biol Reprod 57: 514–519

    Article  PubMed  CAS  Google Scholar 

  37. Bulun SE, Yang S, Fang Z, Gurates B et al. (2001) Role of of aromatase in endometrial disease. J Steroid Biochem Mol Biol 79: 19–25

    Article  PubMed  CAS  Google Scholar 

  38. Takayama K, Zeitoun K, Gunby RT, Sasano H et al. (1998) Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 69: 709–713

    Article  PubMed  CAS  Google Scholar 

  39. Zeitoun K, Takayama K, Gunby RT, Carr BR et al. (1998) Treatment of severe endometriosis with an aromatase inhibitor: A novel indication and its molecular basis. J Soc Gynecol Invest 5(Suppl): 96a

    Article  Google Scholar 

  40. Razzi S, Fava A, Sartini A, De Simone S et al. (2004) Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomized woman. Br J Obstet Gynaecol 111: 182–184

    Google Scholar 

  41. Scarpellini F, Sbracia M (1998) Aromatase Inhibitors in the treatment of severe endometriosis. Fertil Steril 70(Suppl 1): Abstract 009

    Google Scholar 

  42. Scarpellini F, Sbracia M (2000) Aromatase inhibitors in the treatment of severe endometriosis. Proc ESHRE Abstract O-097

    Google Scholar 

  43. Scarpellini F, Sbracia M (2000) Aromatase inhibitors in the treatment of low responder women with severe endometriosis. Fertil Steril 72(Suppl): Abstract P-384

    Google Scholar 

  44. Ailawadi RK, Jobanputra S, Kataria M, Gurates B et al. (2004) Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 81: 290–296

    Article  PubMed  CAS  Google Scholar 

  45. Soysal S, Soysal ME, Ozer S, Gul N et al. (2004) The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomised trial. Hum Reprod 19: 160–167

    Article  PubMed  Google Scholar 

  46. Shippen ER, West WJ (2004) Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 81: 1395–1398

    Article  PubMed  Google Scholar 

  47. Klemi P, Alanen K, Hietanen S, Grenman S et al. (2003) Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy. Obstet Gynecol 102: 1155–1158

    Article  PubMed  Google Scholar 

  48. Turner KJ, Morley M, Atanassova N, Swanston ID et al. (2000) Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocr 164: 225–238

    Article  PubMed  CAS  Google Scholar 

  49. Raman JD, Schlegel PN (2002) Aromatase inhibitors for male infertility. J Urol 167: 624–629

    Article  PubMed  CAS  Google Scholar 

  50. Holbrook JM, Cohen PG (2003) Aromatase inhibition for the treatment of idiopathic hypogonadotropic hypogonadism in men with premature ejaculation. South Med J 96: 544–547

    Article  PubMed  Google Scholar 

  51. Leder BZ, Rohrer JL, Rubin SD, Gallo J et al. (2004) Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocr Metab 89: 1174–1180

    Article  PubMed  CAS  Google Scholar 

  52. Finkelstein JS, Neer RM, Beverley MD, Biller MK et al. (1992) Osteopenia in men with a history of delayed puberty. N Engl J Med 326: 600–604

    Article  PubMed  CAS  Google Scholar 

  53. Uruena M, Pantsiotou S, Preece MA, Stanhope R (1992) Is testosterone therapy for boys with constitutional delay of growth and puberty associated with impaired final height and suppression of the hypothalamo-pituitary-gonadal axis? Eur J Pediatr 151: 15–18

    Article  PubMed  CAS  Google Scholar 

  54. Stanhope R, Brook CGD (1985) Oxandrolone in low dose for constitutional delay of growth and puberty in boys. Arch Dis Child 60: 379–381

    Article  PubMed  CAS  Google Scholar 

  55. Carani C, Qin K, Simoni M, Faustini-Fustini M et al. (1997) ER: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337: 91–95

    Article  PubMed  CAS  Google Scholar 

  56. Bilezikian JP, Morishima A, Bell J, Grumbach MM (1998) Increased bone mass as a result of oestrogen therapy in a man with aromatase deficiency. N Engl J Med 339: 599–603

    Article  PubMed  CAS  Google Scholar 

  57. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E et al. (2001) A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 357: 1743–1748

    Article  PubMed  CAS  Google Scholar 

  58. Dunkel L, Wickman S (2002) Novel treatment of delayed male puberty with aromatase inhibitors. Horm Res 57(Suppl 2): 44–52

    Article  PubMed  CAS  Google Scholar 

  59. Raivio T, Dunkel L, Wickman S, Janne OA (2004) Serum androgen bioactivity in adolescence: a longitudinal study of boys with constitutional delay of puberty. J Clin Endocr Metab 89: 1188–1192

    Article  PubMed  CAS  Google Scholar 

  60. Zhou P, Shah B, Prasad K, David R (2005) Letrozole significantly improves growth potential in a pubertal boy with growth hormone deficiency. Pediatrics 115: E245–E249

    Article  PubMed  Google Scholar 

  61. Wickman S, Kanjantie E, Dunkel L (2003) Effects of suppression of oestrogen action by the P450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocr Metab 88: 3785–3793

    Article  PubMed  CAS  Google Scholar 

  62. Wickman S, Saukkonen T, Dunkel L (2002) The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450 aromatase inhibitor. Eur J Endocr 146: 339–346

    Article  CAS  Google Scholar 

  63. Mauras N, O’Brien KO, Klein KO, Hayes V (2000) Estrogen suppression in males: metabolic effects. J Clin Endocr Metab 85: 2370–2377

    Article  PubMed  CAS  Google Scholar 

  64. Mauras N, Hayes V, O’Brien KO (2000) Estrogen treatment and estrogen suppression: metabolic effects in adolescence. J Paediatr Endocr Metab 13: 1431–1437

    Google Scholar 

  65. Roth C, Freiberg C, Zappel H, Albers N (2002) Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright Syndrome. J Paediatr Endocr Metab 15(Suppl 3): 945–948

    Google Scholar 

  66. Braunstein G (1993) Gynecomastia. N Engl J Med 328: 490–495

    Article  PubMed  CAS  Google Scholar 

  67. Riepe FG, Baus I, Wiest S, Krone N et al. (2004) Treatment of pubertal gynaecomastia with the specific Aromatase Inhibitor Anastrozole. Horm Res 62: 113–118

    Article  PubMed  CAS  Google Scholar 

  68. Plourde PV, Reiter EO, Jou H-C, Desrochers PE et al. (2004) Safety and efficacy of Anastrozole for the treatment of pubertal gynecomastia: a randomised, double-blind, placebo-controlled trial. J Clin Endocr Metab 89: 4428–4433

    Article  PubMed  CAS  Google Scholar 

  69. Saltzstein D, Cantwell A, Sieber P, Ross JR et al. (2002) Prophylactic tamoxifen significantly reduced the incidence of bicalutamide-induced gynaecomastia and breast pain. BJU International 90(Suppl 2): 120–121

    Google Scholar 

  70. Boccardo F, Rubagotti A, Garofalo L, Di Tonni P et al. (2003) Tamoxifen (T) is more effective than anastrozole (A) in preventing gynaecomastia induced by bicalutamide (B) monotherapy in prostate cancer (pca) patients (pts). ASCO Proc 22: 400 Abstract 1608

    Google Scholar 

  71. Conti G, Cretarola E, Boccardo F, Battaglia et al. (2004) Tamoxifen is safe and effective in preventing gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer and does not alter treatment efficacy. Eur Urol (Suppl) 3: 58

    Google Scholar 

  72. Knight JS, Satchidanand R, Cummings MH, Jackson A et al. (2004) A double-blind, randomised, controlled trial to evaluate the effect of anastrozole for the treatment of non-toxic multinodular goitre. Br J Surg 91(Suppl 1): 57

    Google Scholar 

  73. Knight HS, Yagat R, Yiangou C, Jackson A (2004) A double blind randomised controlled trial to evaluate the effect of anastrozole on non-toxic multinodular goitre. Clin Sci 106: 9P

    Google Scholar 

  74. Eshet R, Maor G, Ben Ari T, Eliezer MB et al. (2004) The aromatase inhibitor letrozole increases epiphyseal growth plate height and tibial length in peripubertal male mice. J Endocrinol 182: 165–172

    Article  PubMed  CAS  Google Scholar 

  75. Shih C, Pan MH, Chu P (2000) Effects of estradiol and testosterone/proscar/arimidex on ORX-induced osteopenia in aged rats. J Bone Min Res 15: S343

    Google Scholar 

  76. Goss PE, Qi S, Josse RG, Pritzker ?? et al. (2004) The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34: 384–392

    Article  PubMed  CAS  Google Scholar 

  77. Goss PE, Thomson T, Banke-Bochita J, Lowery C et al. (2002) A randomised placebo-controlled explorative study to investigate the effect of low oestrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12 week treatment with exemestane or letrozole. Breast Cancer Res Treat 76(Suppl 1): S76

    Google Scholar 

  78. Baum M, Budzar AU, Cuczick J, Forbes J et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer; first results of the ATAC randomised trial. Lancet 359: 2131–2139 (Erratum, Lancet 360: 1520)

    Article  PubMed  CAS  Google Scholar 

  79. Eastell R, Adams J (2002) Results of the ‘Arimidex’ (anastrozole, A), tamoxifen (T), alone or in combination (C ) (ATAC) trial: effects on bone mineral density (BMD) and bone turnover. Ann Oncol 13(Suppl 5): 32

    Google Scholar 

  80. Wojtacki J, Zielinski KW, Lesniewski-Kmak K, Wiraszka R et al. (2003) Effect of anastrozole therapy on bone: preliminary results of digital radiometrical analysis of clavicle and rib. Eur J Cancer (Suppl 1): S120

    Google Scholar 

  81. Lai JM, Taxel P, Raisz LG (1998) The effect of aromatase inhibition on bone turnover in older men. J Am Ger Soc 46: S79

    Google Scholar 

  82. Taxel P, Kennedy DG, Fall PM, Willard AK et al. (2001) The effect of aromatase inhibition on sex steroids, Gonadotropins, and markers of bone turnover in older men. J Clin Endocr Metab 86: 2869–2874

    Article  PubMed  CAS  Google Scholar 

  83. Leder BZ, Rohrer JL, Rubin SD, Gallo J et al. (2003) Aromatase inhibition does not alter bone turnover, serum OPG or bone density in elderly men with mild hypogonadism. J Bone Min Res 18(Suppl 2): S42

    Google Scholar 

  84. Goss PE, Ingle JN, Martino S, Rober NJ et al. (2003) A randomised trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802

    Article  PubMed  CAS  Google Scholar 

  85. Harper-Wynne C, Ross G, Sacks N, Dowsett M (2001) A pilot prevention study of the aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. Breast Cancer Res Treat 69: 225

    Google Scholar 

  86. ATAC Trialists’ Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 98: 1802–1810

    Article  CAS  Google Scholar 

  87. Coombes R, Hall E, Gibson LJ, Paridaens R et al. (2004) A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092

    Article  PubMed  CAS  Google Scholar 

  88. Howell A, Cuzick J (2005) Vascular effects of aromatase inhibitors; data from clinical trials. J Steroid Biochem Mol Biol 95: 143–149

    Article  PubMed  CAS  Google Scholar 

  89. Sawada S, Sato K (2003) Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. Breast Cancer Res Treat 82(Suppl 1): S31–S32

    Google Scholar 

  90. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B et al. (2001) Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37: 1510–1513

    Article  PubMed  CAS  Google Scholar 

  91. Harper-Wynne C, Ross G, Sacks N, Salters J et al. (2002) Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11: 614–621

    PubMed  CAS  Google Scholar 

  92. Engen T, Krane J, Johannessen DC, Lonning PE et al. (1995) Plasma changes in breast cancer patients during endocrine therapy — lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 36: 287–297

    Article  Google Scholar 

  93. Lohrisch C, Paridaens R, Dirix LY, Beex L et al. (2001) No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (Exemestane (E) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European Organisation of Research and Treatment of Cancer. (Breast Group) trial with exemestane. Proc Am Soc Clin Oncol 20: 43a

    Google Scholar 

  94. Atalay G, Dirix L, Biganzoli L, Beex L et al. (2004) The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 1095, “randomised phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients”. Ann Oncol 15: 211–21

    Article  PubMed  CAS  Google Scholar 

  95. Cherrier MM, Asthana S, Plymate S, Baker LD et al. (2000) Cognitive effects from exogenous manipulation of testosterone and estradiol in older men. Soc Neurosci 26: 13

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Global Discovery, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

    Barrington J. A. Furr

Authors
  1. Barrington J. A. Furr
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Global Discovery, AstraZeneca, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK

    Barrington J. A. Furr

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Furr, B.J.A. (2008). Possible additional therapeutic uses of aromatase inhibitors. In: Furr, B.J.A. (eds) Aromatase Inhibitors. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8693-1_9

Download citation

Publish with us

Policies and ethics

Search

Navigation